SK-1403 Long-term Treatment Study - Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis -
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs SK 1403 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational
- Sponsors Sanwa Kagaku Kenkyusho
- 21 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.
- 21 Aug 2018 New trial record